| Name | ACP-105 |
| Description | ACP-105 is a novel and potent nonsteroidal selective androgen receptor modulator (SARM) with partial agonist activity relative to the natural androgen testosterone. |
| In vitro | ACP-105 is an orally administered, selective, and potent androgen receptor modulator (SARM), demonstrating high affinity with pEC50 values of 9.0 and 9.3 for the AR wild type and T877A mutant, respectively. In human hepatocytes, the half-life of ACP-105 (compound 1) is determined to be 5.0 hours[1]. |
| In vivo | Irradiation impaired sensorimotor function in vehicle-treated mice but not in ACP-105-treated mice. Irradiation impaired cued fear conditioning and ACP-105 enhanced fear conditioning in sham-irradiated and irradiated mice. There are relatively early radiation-induced behavioral changes in female mice and reduced MAP-2 levels in the sensorimotor cortex following ACP-105 treatment might contribute to enhanced rotorod performance[2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 60 mg/mL (206.33 mM), Sonication is recommended.
Ethanol : 60 mg/mL (206.33 mM)
|
| Keywords | ACP 105 | inhibit | ACP-105 | ACP105 | Inhibitor | Androgen Receptor |
| Inhibitors Related | Dehydroisoandrosterone 3-acetate | Bicalutamide | 2,2,5,7,8-Pentamethyl-6-Chromanol | S-23 | Bavdegalutamide | Enzalutamide | Adrenosterone | Allura Red AC | SK33 | Sunset Yellow FCF | Ostarine | Flutamide |
| Related Compound Libraries | Nuclear Receptor Compound Library | Bioactive Compound Library | Anti-Prostate Cancer Compound Library | Endocrinology-Hormone Compound Library | Orally Active Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Transcription Factor-Targeted Compound Library |
United States
